卵巢癌术前分期:超声、CT与全身弥散加权MRI的比较(ISAAC研究)
该前瞻性研究纳入67例疑似卵巢癌患者,对比经阴道/经腹超声、增强CT和全身弥散加权MRI在腹膜癌病、淋巴结分期及不可切除性预测中的表现。结果显示超声与WB-DWI/MRI在整体腹膜癌病评估中均优于CT,且超声不劣于CT;三种方法在腹膜后淋巴结分期和腹部不可切除性预测中表现相似。超声在盆腔癌病和直肠乙状结肠深肌层浸润评估中准确度和敏感度最高。
要点
- 超声评估整体腹膜癌病的AUC为0.87,不劣于CT(P=0.002),且优于CT的0.77。
- 经阴道超声检测盆腔癌病的准确度94%、敏感度94%,高于WB-DWI/MRI和CT。
- 超声评估直肠乙状结肠深肌层浸润的准确度93%、敏感度100%,有助于规划直肠乙状结肠切除。
关键影像表现/征象
- 超声和WB-DWI/MRI评估整体腹膜癌病的AUC分别为0.87和0.86,均优于CT的0.77。
- 在19个腹膜评估部位中,超声的特异度普遍高于或等于WB-DWI/MRI和CT,但腹部敏感度较低或相等。
- 经阴道超声检测盆腔癌病的准确度为94%、敏感度为94%,高于WB-DWI/MRI(91%、91%)和CT(85%、89%)。
- 超声评估直肠乙状结肠深肌层浸润的准确度93%、敏感度100%,优于WB-DWI/MRI(83%、75%)和CT(84%、88%)。
- 腹部超声评估肠浆膜和肠系膜的准确度最低(70%),敏感度也最低(42%),低于WB-DWI/MRI(78%、65%)和CT(79%、65%)。
诊断标准与关键数值
- 腹膜癌病评估采用19个腹膜部位,淋巴结评估采用8个部位,不可切除性预测基于腹部标志物。
- 整体腹膜癌病AUC:超声0.87、WB-DWI/MRI 0.86、CT 0.77;超声不劣于CT(P=0.002)。
- 腹膜后淋巴结分期AUC为0.72-0.76,腹部不可切除性预测AUC为0.74-0.80,三种方法表现相似。
临床应用与阅片要点
- 经阴道超声对盆腔癌病和直肠乙状结肠深肌层浸润评估价值高,可辅助规划直肠乙状结肠切除。
- 腹部超声对肠浆膜和肠系膜评估敏感度低,需结合WB-DWI/MRI或CT综合判断。
- 超声评估腹膜癌病特异度高,但腹部敏感度较低,阴性时仍需警惕腹部病变。
局限性
- 单中心研究,样本量67例,结果需外推验证。
- 超声表现依赖操作者经验,研究未设盲法描述。
- 未报告阅片者间一致性及设备具体参数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare the performance of transvaginal and transabdominal ultrasound with that of the first-line staging method (contrast-enhanced computed tomography (CT)) and a novel technique, whole-body magnetic resonance imaging with diffusion-weighted sequence (WB-DWI/MRI), in the assessment of peritoneal involvement (carcinomatosis), lymph-node staging and prediction of non-resectability in patients with suspected ovarian cancer.
METHODS: Between March 2016 and October 2017, all consecutive patients with suspicion of ovarian cancer and surgery planned at a gynecological oncology center underwent preoperative staging and prediction of non-resectability with ultrasound, CT and WB-DWI/MRI. The evaluation followed a single, predefined protocol, assessing peritoneal spread at 19 sites and lymph-node metastasis at eight sites. The prediction of non-resectability was based on abdominal markers. Findings were compared to the reference standard (surgical findings and outcome and histopathological evaluation).
RESULTS: Sixty-seven patients with confirmed ovarian cancer were analyzed. Among them, 51 (76%) had advanced-stage and 16 (24%) had early-stage ovarian cancer. Diagnostic laparoscopy only was performed in 16% (11/67) of the cases and laparotomy in 84% (56/67), with no residual disease at the end of surgery in 68% (38/56), residual disease ≤ 1 cm in 16% (9/56) and residual disease > 1 cm in 16% (9/56). Ultrasound and WB-DWI/MRI performed better than did CT in the assessment of overall peritoneal carcinomatosis (area under the receiver-operating-characteristics curve (AUC), 0.87, 0.86 and 0.77, respectively). Ultrasound was not inferior to CT (P = 0.002). For assessment of retroperitoneal lymph-node staging (AUC, 0.72-0.76) and prediction of non-resectability in the abdomen (AUC, 0.74-0.80), all three methods performed similarly. In general, ultrasound had higher or identical specificity to WB-DWI/MRI and CT at each of the 19 peritoneal sites evaluated, but lower or equal sensitivity in the abdomen. Compared with WB-DWI/MRI and CT, transvaginal ultrasound had higher accuracy (94% vs 91% and 85%, respectively) and sensitivity (94% vs 91% and 89%, respectively) in the detection of carcinomatosis in the pelvis. Better accuracy and sensitivity of ultrasound (93% and 100%) than WB-DWI/MRI (83% and 75%) and CT (84% and 88%) in the evaluation of deep rectosigmoid wall infiltration, in particular, supports the potential role of ultrasound in planning rectosigmoid resection. In contrast, for the bowel serosal and mesenterial assessment, abdominal ultrasound had the lowest accuracy (70%, 78% and 79%, respectively) and sensitivity (42%, 65% and 65%, respectively).
CONCLUSIONS: This is the first prospective study to document that, in experienced hands, ultrasound may be an alternative to WB-DWI/MRI and CT in ovarian cancer staging, including peritoneal and lymph-node evaluation and prediction of non-resectability based on abdominal markers of non-resectability. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Fischerova D, Pinto P, Burgetova A, et al. Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole-body diffusion-weighted MRI (ISAAC study). Ultrasound Obstet Gynecol. 2022. PMID: 33871110. doi:10.1002/uog.23654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。